FMP

FMP

Enter

SKYE - Skye Bioscience, Inc.

Profile of Skye Bioscience, Inc.(SKYE), Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabin

About

ceo

Mr. Punit S. Dhillon B.A., BA

sector

Healthcare

industry

Biotechnology

website

https://skyebioscience.com

exchange

PNK

Description

Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.

CIK

0001516551

ISIN

US83086J2006

CUSIP

83086J101

Address

11250 El Camino Real

Phone

858 410 0266

Country

US

Employee

11

IPO Date

Nov 26, 2014

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep